目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T83972 | GPR | ||
NOX-6-18 (GPR132-B-160) 是一种具有高效性和选择性的 GPR132 拮抗剂,具有促进胰岛素分泌活性,可以调节胰岛内的巨噬细胞重编程,减少体重增加。 | |||
T73718 | Endogenous Metabolite | ||
MDCG sodium (N-methyl-N-dithiocarboxyglucamine sodium) 是一种金属螯合剂,可促进Cd的胆道排泄。 | |||
T4359 | NADPH | ||
VAS2870 是一种NADPH 氧化酶抑制剂。 | |||
T8107 | NADPH-oxidase NADPH | ||
GLX351322 抑制 NADPH 氧化酶 4 (Nox4) 。在 NOX4 过表达的细胞中,抑制过氧化氢的产生,IC50值为 5 μM。 | |||
T15433 | Apoptosis Reactive Oxygen Species ROS NADPH | ||
GSK2795039 是一种 NADPH 氧化酶 2 抑制剂,可抑制活性氧产生和 NADPH 消耗,同时可减少细胞凋亡。 | |||
T33716 | Endogenous Metabolite | ||
Norathiol (N-methyl-N-dithiocarboxyglucamine) 是一种镉中毒解毒剂,也是一种金属螯合剂,可促进 109Cd 的排泄,可以用于治疗镉中毒。 | |||
T22990 | NADPH-oxidase Others | ||
ML-090 是 NOX1 特异性抑制剂 (IC50 = 90 nM),对 NOX1 的特异性高于 NOX2、NOX3、NOX4(所有 IC50 > 10 μM)100倍。 | |||
T6099 | NADPH-oxidase Ferroptosis NADPH | ||
Setanaxib (GKT137831) 是一种有效的特异性双重 NADPH 氧化酶 (NOX1/4) 抑制剂,Ki 分别为140和110nM。 | |||
T68796 | |||
Thr101, also known as NOX Inhibitor VII, is a dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9. Thr101 is also a NOX inhibitor. | |||
T7191 | NOS Reactive Oxygen Species NADPH TRP/TRPV Channel | ||
Diphenyleneiodonium chloride (DPI) 是 NADPH 氧化酶抑制剂,也是 TRPA1激活剂,EC50为 1 - 3 μM 。它选择性抑制胞内活性氧。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-01276 | ENOX1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 24 minutes and play a role in control of the ultradian cellular biological clock.
|
|||||
TMPJ-00848 | NCF1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Neutrophil cytosol factor 1( NCF1) is a 47 kDa cytosolic subunit of neutrophil NADPH oxidase. This oxidase is characterized as a multicomponent enzyme which is activated to produce superoxide anion. NCF2, NCF1, and a membrane bound cytochrome b558 are required for the activation of the latent NADPH oxidase. The human NCF1 gene encodes a 390 amino acids protein without a signal peptide. The NCF1 gene interacts with other subunits of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) and plays an important role in innate immunity, producing reactive oxygen species and reducing the severity and duration of parasitic infection and autoimmune disease. NCF1 also has a role in T cell activation.
|
|||||
TMPH-01744 | NOX1 Protein, Human, Recombinant (His) | Human | E. coli | ||
NOH-1S is a voltage-gated proton channel that mediates the H(+) currents of resting phagocytes and other tissues. It participates in the regulation of cellular pH and is blocked by zinc. NOH-1L is a pyridine nucleotide-dependent oxidoreductase that generates superoxide and might conduct H(+) ions as part of its electron transport mechanism, whereas NOH-1S does not contain an electron transport chain. NOX1 Protein, Human, Recombinant (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 67.7 kDa and the accession number is Q9Y5S8.
|
|||||
TMPH-01278 | ENOX2 Protein, Human, Recombinant (His & Myc) | Human | E. coli | ||
May be involved in cell growth. Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 22 minutes and play a role in control of the ultradian cellular biological clock.
|
|||||
TMPH-01277 | ENOX2 Protein, Human, Recombinant | Human | E. coli | ||
May be involved in cell growth. Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 22 minutes and play a role in control of the ultradian cellular biological clock.
|
|||||
TMPH-01745 | NOX4 Protein, Human, Recombinant (Cell-Free, His) | Human | E. coli | ||
NOX4 Protein, Human, Recombinant (Cell-Free, His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 69.8?kDa and the accession number is Q9NPH5.
|
|||||
TMPH-01746 | NOX4 Protein, Human, Recombinant (E. coli, His) | Human | E. coli | ||
NOX4 Protein, Human, Recombinant (E. coli, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 28.8 kDa and the accession number is Q9NPH5.
|
|||||
TMPY-02391 | SUMO1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Small ubiquitin-like modifier protein (SUMO) modification is a highly dynamic process, catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes, and reversed by a family of SUMO-specific proteases (SENPs). Small ubiquitin-like modifier 1 (SUMO1) is a member of the superfamily of ubiquitin-like proteins. Despite its structural similarity with ubiquitin, SUMO1 does not seem to play any role in protein degradation. SUMO1 plays an important role in modulation of NOX activity required for ROS generation. SUMO1 haploinsufficiency results in cleft lip and palate in animal models. SUMO1 gene variation in human non-syndromic cleft lip with or without cleft palate (NSCLP) development. SUMO-1 may be useful as a novel target for therapy in oral squamous cell carcinoma (SCC) as well as a clinical indicator for tumor recurrence together with Mdm2.
|